BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  applicant  Novartis  Europharm  Limited  submitted  on  01  December  2006  an  application  for 
Marketing  Authorisation  to  the  European  Medicines  Agency  (EMEA)  for  Eucreas,  through  the 
centralised  procedure  falling  within  the  Article  3(1)  and  point  3  of  Annex  of  Regulation  (EC)  No 
726/2004.  The  eligibility  to  the  centralised  procedure  was  agreed  upon  by  the  EMEA/CHMP  on  21 
September 2006 
The  legal  basis  for  this  application  refers  to  Article  8.3  of  Directive  2001/83/EC,  as  amended  - 
complete and independent application. 
The application submitted is a complete dossier: composed of administrative information, complete 
quality data, non-clinical and clinical data based on applicants’ own tests and studies and bibliographic 
literature substituting or supporting certain tests or studies. 
The applicant applied for an indication treatment of type 2 diabetes mellitus.  
Licensing status: 
The product was not licensed in any country at the time of submission of the application. 
The Rapporteur and Co-Rapporteur appointed by the CHMP were: 
Rapporteur: Bengt Ljungberg  Co-Rapporteur: Pierre Demolis 
2. 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
The application was received by the EMEA on 01 December 2006. 
The procedure started on 24 January 2007.  
The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on  13  April 
2007. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 17 
April 2007.  
During the meeting on 24 May 2007 the CHMP agreed on the consolidated List of Questions to 
be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 24 
May 2007. 
The applicant submitted the responses to the CHMP consolidated List of Questions on 13 July 
2007. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Questions to all CHMP members on 31 August 2007. 
During  the  meeting  on  17-20  September  2007,  the  CHMP,  in  the  light  of  the  overall  data 
submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for 
granting a Marketing Authorisation to EUCREAS on 20 September. The applicant provided the 
letter  of  undertaking  on  the  follow-up  measures  to  be  fulfilled  post-authorisation  on  17 
September 2007. 
1/1 
© EMEA 2007 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
